KYTHERA Biopharmaceuticals to Present at Leerink Swann Global Healthcare Conference

Updated

KYTHERA Biopharmaceuticals to Present at Leerink Swann Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (NAS: KYTH) today announced that Keith Leonard, President and Chief Executive Officer, will present at the Leerink Swann Global Healthcare Conference 2013 in New York.

Event:

Leerink Swann Global Healthcare Conference 2013, New York

Date:

Wednesday, Feb. 13, 2013

Time:

3 p.m. EST

A live webcast will be available on the Company's website at www.kytherabiopharma.com under the Investors section of the website. The presentation will be archived on the website and will be available for at least 14 days.


About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is a potential first-in-class, injectable treatment currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at http://www.kytherabiopharma.com.



KYTHERA Biopharmaceuticals, Inc.
Heather Rowe
Associate Director, Investor Relations
818-587-4559
hrowe@kytherabiopharma.com

KEYWORDS: United States North America California

INDUSTRY KEYWORDS:

The article KYTHERA Biopharmaceuticals to Present at Leerink Swann Global Healthcare Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement